dronabinol has been researched along with Dermatomyositis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bashir, MM; Bax, C; Chen, KL; Concha, JSS; Diaz, A; Grinnell, M; Li, Y; Maddukuri, S; Okawa, J; Patel, J; Ravishankar, A; Reddy, N; Werth, VP; White, B; Wysocka, M; Zeidi, M | 1 |
| Bashir, MM; Concha, JSS; Constantine, S; Dgetluck, N; Feng, R; Gebre, K; Haber, J; Hejazi, E; Jadoo, AS; Okawa, J; Pena, SM; Reddy, N; Werth, VP; White, B; Zeidi, M | 1 |
| Alves, P; Bashir, MM; Feng, R; Robinson, ES; Werth, VP; Zeidi, M | 1 |
1 trial(s) available for dronabinol and Dermatomyositis
| Article | Year |
|---|---|
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Biomarkers; Cannabinoid Receptor Agonists; Dermatomyositis; Double-Blind Method; Dronabinol; Humans; Hydroxychloroquine; Receptors, Cannabinoid; Treatment Outcome | 2022 |
2 other study(ies) available for dronabinol and Dermatomyositis
| Article | Year |
|---|---|
Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum
Topics: Dermatomyositis; Dronabinol; Humans; Leukocytes, Mononuclear; Receptors, Cannabinoid | 2022 |
Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro.
Topics: Cannabinoids; Cohort Studies; Cytokines; Dermatomyositis; Dronabinol; Humans; In Vitro Techniques; Interferon Type I; Prospective Studies; Sensitivity and Specificity; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2017 |